Thrombophilia and the Risk for Venous Thromboembolism during Pregnancy, Delivery, and Puerperium

Obstetrics and Gynecology Clinics of North America

Volumn 33, Issue 3, 2006, Pages 413-427

  Nelson, Scott M ^a   Greer, Ian A ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; PROCOAGULANT; PROTEIN C; PROTEIN S; PROTHROMBIN;

ANTITHROMBIN DEFICIENCY; DELIVERY; FEMALE; GENETIC VARIABILITY; HOMOZYGOTE; HUMAN; MATERNAL CARE; MEDICAL SPECIALIST; OBSTETRICS; PERINATAL CARE; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; PUERPERIUM; REVIEW; RISK FACTOR; THROMBOPHILIA; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; WESTERN EUROPE;

FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MASS SCREENING; OBSTETRIC LABOR COMPLICATIONS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PUERPERAL DISORDERS; RISK FACTORS; THROMBOEMBOLISM; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 33748309338     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ogc.2006.05.009     Document Type: Review

References (48)

1. The National Institute for Clinical Excellence SEHDaDoHSSaPSNI. Why mothers die-report on confidential enquiries into maternal deaths in the United Kingdom 2000-2002 (2003), TSO, London
2. Hogberg U., Innala E., and Sandstrom A. Maternal mortality in Sweden, 1980-1988. Obstet Gynecol 84 2 (1994) 240-244
3. Walker I.D. Congenital thrombophilia. Baillieres Clin Obstet Gynaecol 11 3 (1997) 431-445
4. Zheng H., Tzeng C.C., Butt C., et al. An extremely low prevalence of FVL, FIIG20210A and FXIIIV34L in Taiwan Chinese population. Thromb Haemost 87 6 (2002) 1081-1082
5. Zoller B., Holm J., and Dahlback B. Resistance to activated protein C due to a factor V gene mutation: the most common inherited risk factor of thrombosis. Trends Cardiovasc Med 6 2 (1996) 45-53
6. Margaglione M., Bossone A., Coalizzo D., et al. FV HR2 haplotype as additional inherited risk factor for deep vein thrombosis in individuals with a high-risk profile. Thromb Haemost 87 1 (2002) 32-36
7. Clark P., Brennand J., Conkie J.A., et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 79 6 (1998) 1166-1170
8. Poort S.R., Rosendaal F.R., Reitsma P.H., et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88 10 (1996) 3698-3703
9. McColl M.D., Walker I.D., and Greer I.A. A mutation in the prothrombin gene contributing to venous thrombosis during pregnancy. Br J Obstet Gynaecol 105 8 (1998) 923-925
10. McColl M.D., Ellison J., Reid F., et al. Prothrombin 20210 G→A, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy. Br J Obstet Gynaecol 107 4 (2000) 565-569
11. Gerhardt A., Scharf R.E., Beckmann M.W., et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 342 6 (2000) 374-380
12. Ellison J., Clark P., Walker I.D., et al. Effect of supplementation with folic acid throughout pregnancy on plasma homocysteine concentration. Thromb Res 114 1 (2004) 25-27
13. Greer I.A. Thrombosis in pregnancy: maternal and fetal issues. Lancet 353 9160 (1999) 1258-1265
14. Rosendaal F.R. Venous thrombosis: a multicausal disease. Lancet 353 9159 (1999) 1167-1173
15. Macklon N.S., and Greer I.A. Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience. Scott Med J 41 3 (1996) 83-86
16. Rosendaal F.R. Venous thrombosis: the role of genes, environment, and behavior. Hematology Am Soc Hematol Educ Prog (2005) 1-12
17. Conard J., Horellou M.H., Van Dreden P., et al. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost 63 2 (1990) 319-320
18. De Stefano V., Leone G., Mastrangelo S., et al. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 71 6 (1994) 799-800
19. Robertson L., Wu O., Langhorne P., et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 132 (2005) 171-196
20. Langlois N.J., and Wells P.S. Risk of venous thromboembolism in relatives of symptomatic probands with thrombophilia: a systematic review. Thromb Haemost 90 1 (2003) 17-26
21. Martinelli I., De S.V., Taioli E., et al. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost 87 5 (2002) 791-795
22. McColl M.D., Ramsay J.E., Tait R.C., et al. Risk factors for pregnancy-associated venous thromboembolism. Thromb Haemost 78 4 (1997) 1183-1188
23. Macklon N.S., Greer I.A., and Bowman A.W. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. Br J Obstet Gynaecol 104 2 (1997) 191-197
24. Macklon N.S., and Greer I.A. The deep venous system in the puerperium: an ultrasound study. Br J Obstet Gynaecol 104 2 (1997) 198-200
25. Kodama H., Fukuda J., Karube H., et al. Status of the coagulation and fibrinolytic systems in ovarian hyperstimulation syndrome. Fertil Steril 66 3 (1996) 417-424
26. Arya R., Shehata H.A., Patel R.K., et al. Internal jugular vein thrombosis after assisted conception therapy. Br J Haematol 115 1 (2001) 153-155
27. Voss M., Cole R., Moriarty T., et al. Thromboembolic disease and air travel in pregnancy: a survey of advice given by obstetricians. J Obstet Gynaecol 24 8 (2004) 859-862
28. Chee Y.L., and Watson H.G. Air travel and thrombosis. Br J Haematol 130 5 (2005) 671-680
29. Pabinger I., Grafenhofer H., Kyrle P.A., et al. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood 100 3 (2002) 1060-1062
30. Bates S.M., Greer I.A., Hirsh J., et al. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 627S-44
31. Rai R., Cohen H., Dave M., et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 314 7076 (1997) 253-257
32. Clark P., Twaddle S., Walker I.D., et al. Cost-effectiveness of screening for the FVL mutation in pregnant women. Lancet 359 9321 (2002) 1919-1920
33. Wu O., Robertson L., Twaddle S., et al. Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol 131 1 (2005) 80-90
34. Petrou S. The economic consequences of preterm birth during the first 10 years of life. Br J Obstet Gynaecol 112 Suppl 1 (2005) 10-15
35. Bates S.M., and Ginsberg J.S. Anticoagulants in pregnancy: fetal effects. Baillieres Clin Obstet Gynaecol 11 3 (1997) 479-488
36. Wesseling J., Van Driel D., Heymans H.S.A., et al. Coumarins during pregnancy: long-term effects on growth and development of school-age children. Thromb Haemost 85 4 (2001) 609-613
37. Flessa H.C., Kapstrom A.B., Glueck H.I., et al. Placental transport of heparin. Am J Obstet Gynecol 93 4 (1965) 570-573
38. Forestier F., Daffos F., and Capella-Pavlovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Thromb Res 34 6 (1984) 557-560
39. Forestier F., Daffos F., Rainaut M., et al. Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy. Thromb Haemost 57 2 (1987) 234
40. Greer I.A. Prevention and management of venous thromboembolism in pregnancy. Clin Chest Med 24 1 (2003) 123-137
41. Nelson-Piercy C. Hazards of heparin: allergy, heparin-induced thrombocytopenia and osteoporosis. Baillieres Clin Obstet Gynaecol 11 3 (1997) 489-509
42. Greer I.A., and Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 106 2 (2005) 401-407
43. Brill-Edwards P., Ginsberg J.S., Gent M., et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med 343 20 (2000) 1439-1444
44. Waterstone M., Bewley S., and Wolfe C. Incidence and predictors of severe obstetric morbidity: case-control study. BMJ 322 7294 (2001) 1089-1093
45. Burrows R.F., and Kelton J.G. Thrombocytopenia at delivery: a prospective survey of 6715 deliveries. Am J Obstet Gynecol 162 3 (1990) 731-734
46. Warkentin T.E., and Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 311S-37
47. Byrd L., Johnston T.A., Shiach C., et al. Osteoporotic fracture and low molecular weight heparin. J Obstet Gynaecol 24 Suppl 1 (2004) S11
48. Pabinger I., Grafenhofer H., Kaider A., et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost 3 5 (2005) 949-954